Molecular diagnostics, personalized medicine, and the evolving role of the cytotechnologist: An institutional experience

Lindsey E. Kane, Renee R. Root, Jesse S. Voss, Jill L. Caudill, Angela M. Sorenson, Lisa K. Colborn, Kevin C. Halling, Michael R. Henry, Amy C. Clayton, Benjamin R. Kipp

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The role of cytotechnologists has focused primarily on the microscopic examination of cytologic specimens for diagnosing disease. Cytotechnologists currently evaluate a wide assortment of both gynecological and nongynecological cytology specimens. However, the Pap test remains the primary test for most cytology laboratories. Recently, human papillomavirus testing and newer cervical cancer screening guidelines have reduced the number of Pap tests, resulting in some anxiety and concern among the cytology community. However, as Pap test volumes continue to decrease, molecular oncology and ancillary testing volumes continue to increase with the advent of new biomarkers and associated personalized therapies. This change in clinical practice has resulted in evolving roles for many cytotechnologists. Cytotechnologists have skills based not only in morphology but also in understanding concepts of disease including neoplasia. These skills allow cytotechnologists to excel in many other types of laboratory testing. This article discusses how the roles of the cytotechnologist have recently expanded at our institution to include involvement in DNA ploidy analysis, quantitative immunohistochemistry, fluorescence in situ hybridization, circulating tumor cells, and molecular oncology testing. Lastly, this article discusses how these newer roles benefit both the cytotechnologist and the clinical laboratory.

Original languageEnglish (US)
Pages (from-to)678-685
Number of pages8
JournalActa Cytologica
Volume56
Issue number6
DOIs
StatePublished - Nov 2012

Fingerprint

Papanicolaou Test
Precision Medicine
Molecular Pathology
Cell Biology
Circulating Neoplastic Cells
Ploidies
Fluorescence In Situ Hybridization
Early Detection of Cancer
Uterine Cervical Neoplasms
Anxiety
Biomarkers
Immunohistochemistry
Guidelines
DNA
Neoplasms
Therapeutics

Keywords

  • Ancillary testing
  • Cytology
  • Molecular diagnostics
  • Molecular pathology

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

Kane, L. E., Root, R. R., Voss, J. S., Caudill, J. L., Sorenson, A. M., Colborn, L. K., ... Kipp, B. R. (2012). Molecular diagnostics, personalized medicine, and the evolving role of the cytotechnologist: An institutional experience. Acta Cytologica, 56(6), 678-685. https://doi.org/10.1159/000341169

Molecular diagnostics, personalized medicine, and the evolving role of the cytotechnologist : An institutional experience. / Kane, Lindsey E.; Root, Renee R.; Voss, Jesse S.; Caudill, Jill L.; Sorenson, Angela M.; Colborn, Lisa K.; Halling, Kevin C.; Henry, Michael R.; Clayton, Amy C.; Kipp, Benjamin R.

In: Acta Cytologica, Vol. 56, No. 6, 11.2012, p. 678-685.

Research output: Contribution to journalArticle

Kane, LE, Root, RR, Voss, JS, Caudill, JL, Sorenson, AM, Colborn, LK, Halling, KC, Henry, MR, Clayton, AC & Kipp, BR 2012, 'Molecular diagnostics, personalized medicine, and the evolving role of the cytotechnologist: An institutional experience', Acta Cytologica, vol. 56, no. 6, pp. 678-685. https://doi.org/10.1159/000341169
Kane, Lindsey E. ; Root, Renee R. ; Voss, Jesse S. ; Caudill, Jill L. ; Sorenson, Angela M. ; Colborn, Lisa K. ; Halling, Kevin C. ; Henry, Michael R. ; Clayton, Amy C. ; Kipp, Benjamin R. / Molecular diagnostics, personalized medicine, and the evolving role of the cytotechnologist : An institutional experience. In: Acta Cytologica. 2012 ; Vol. 56, No. 6. pp. 678-685.
@article{1523d936f9a6480ca625461c1e9f5e06,
title = "Molecular diagnostics, personalized medicine, and the evolving role of the cytotechnologist: An institutional experience",
abstract = "The role of cytotechnologists has focused primarily on the microscopic examination of cytologic specimens for diagnosing disease. Cytotechnologists currently evaluate a wide assortment of both gynecological and nongynecological cytology specimens. However, the Pap test remains the primary test for most cytology laboratories. Recently, human papillomavirus testing and newer cervical cancer screening guidelines have reduced the number of Pap tests, resulting in some anxiety and concern among the cytology community. However, as Pap test volumes continue to decrease, molecular oncology and ancillary testing volumes continue to increase with the advent of new biomarkers and associated personalized therapies. This change in clinical practice has resulted in evolving roles for many cytotechnologists. Cytotechnologists have skills based not only in morphology but also in understanding concepts of disease including neoplasia. These skills allow cytotechnologists to excel in many other types of laboratory testing. This article discusses how the roles of the cytotechnologist have recently expanded at our institution to include involvement in DNA ploidy analysis, quantitative immunohistochemistry, fluorescence in situ hybridization, circulating tumor cells, and molecular oncology testing. Lastly, this article discusses how these newer roles benefit both the cytotechnologist and the clinical laboratory.",
keywords = "Ancillary testing, Cytology, Molecular diagnostics, Molecular pathology",
author = "Kane, {Lindsey E.} and Root, {Renee R.} and Voss, {Jesse S.} and Caudill, {Jill L.} and Sorenson, {Angela M.} and Colborn, {Lisa K.} and Halling, {Kevin C.} and Henry, {Michael R.} and Clayton, {Amy C.} and Kipp, {Benjamin R.}",
year = "2012",
month = "11",
doi = "10.1159/000341169",
language = "English (US)",
volume = "56",
pages = "678--685",
journal = "Acta Cytologica",
issn = "0001-5547",
publisher = "Science Printers and Publishers Inc.",
number = "6",

}

TY - JOUR

T1 - Molecular diagnostics, personalized medicine, and the evolving role of the cytotechnologist

T2 - An institutional experience

AU - Kane, Lindsey E.

AU - Root, Renee R.

AU - Voss, Jesse S.

AU - Caudill, Jill L.

AU - Sorenson, Angela M.

AU - Colborn, Lisa K.

AU - Halling, Kevin C.

AU - Henry, Michael R.

AU - Clayton, Amy C.

AU - Kipp, Benjamin R.

PY - 2012/11

Y1 - 2012/11

N2 - The role of cytotechnologists has focused primarily on the microscopic examination of cytologic specimens for diagnosing disease. Cytotechnologists currently evaluate a wide assortment of both gynecological and nongynecological cytology specimens. However, the Pap test remains the primary test for most cytology laboratories. Recently, human papillomavirus testing and newer cervical cancer screening guidelines have reduced the number of Pap tests, resulting in some anxiety and concern among the cytology community. However, as Pap test volumes continue to decrease, molecular oncology and ancillary testing volumes continue to increase with the advent of new biomarkers and associated personalized therapies. This change in clinical practice has resulted in evolving roles for many cytotechnologists. Cytotechnologists have skills based not only in morphology but also in understanding concepts of disease including neoplasia. These skills allow cytotechnologists to excel in many other types of laboratory testing. This article discusses how the roles of the cytotechnologist have recently expanded at our institution to include involvement in DNA ploidy analysis, quantitative immunohistochemistry, fluorescence in situ hybridization, circulating tumor cells, and molecular oncology testing. Lastly, this article discusses how these newer roles benefit both the cytotechnologist and the clinical laboratory.

AB - The role of cytotechnologists has focused primarily on the microscopic examination of cytologic specimens for diagnosing disease. Cytotechnologists currently evaluate a wide assortment of both gynecological and nongynecological cytology specimens. However, the Pap test remains the primary test for most cytology laboratories. Recently, human papillomavirus testing and newer cervical cancer screening guidelines have reduced the number of Pap tests, resulting in some anxiety and concern among the cytology community. However, as Pap test volumes continue to decrease, molecular oncology and ancillary testing volumes continue to increase with the advent of new biomarkers and associated personalized therapies. This change in clinical practice has resulted in evolving roles for many cytotechnologists. Cytotechnologists have skills based not only in morphology but also in understanding concepts of disease including neoplasia. These skills allow cytotechnologists to excel in many other types of laboratory testing. This article discusses how the roles of the cytotechnologist have recently expanded at our institution to include involvement in DNA ploidy analysis, quantitative immunohistochemistry, fluorescence in situ hybridization, circulating tumor cells, and molecular oncology testing. Lastly, this article discusses how these newer roles benefit both the cytotechnologist and the clinical laboratory.

KW - Ancillary testing

KW - Cytology

KW - Molecular diagnostics

KW - Molecular pathology

UR - http://www.scopus.com/inward/record.url?scp=84870667353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870667353&partnerID=8YFLogxK

U2 - 10.1159/000341169

DO - 10.1159/000341169

M3 - Article

C2 - 23207447

AN - SCOPUS:84870667353

VL - 56

SP - 678

EP - 685

JO - Acta Cytologica

JF - Acta Cytologica

SN - 0001-5547

IS - 6

ER -